Preventing saphenous vein graft failure: does gene therapy have a role?
Gene therapy potentially allows local delivery and expression of cytokines, growth factors, and other mediators. In spite of increasing knowledge of the human genome, applications in clinical practice are only just beginning. The main limitations of effective clinical gene therapy are safety and low...
Saved in:
Published in | The Annals of Thoracic Surgery Vol. 76; no. 3; pp. 959 - 966 |
---|---|
Main Authors | , , , |
Format | Book Review Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.09.2003
Elsevier Science |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Gene therapy potentially allows local delivery and expression of cytokines, growth factors, and other mediators. In spite of increasing knowledge of the human genome, applications in clinical practice are only just beginning. The main limitations of effective clinical gene therapy are safety and low transfection efficiency. Saphenous vein grafts permit the transfection of the conduit ex vivo. This allows a variety of transfection techniques to be used, enhancing the transfection efficiency while limiting the risk of systemic complications. This review examines the potential mechanisms of gene delivery and genetic targets that may be applied to saphenous vein graft failure. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
ISSN: | 0003-4975 1552-6259 |
DOI: | 10.1016/S0003-4975(03)00505-8 |